Daniel E Rieders, MD
Cardiovascular Disease (Cardiology) · Grass Valley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 19
- 4 carriers
- Offices
- 2
Offices
2 locations · Dignity Health Medical Foundation · County of Santa Clara
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
19 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Rieders’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
19 of 19 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G45077 · Current
Licensed to practise in California · since 1981 · expires 2027-01-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$50,419
Medicare paid this office $50,419 for 287 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 98 | $19,479 | $145 |
| New patient visit (45+ min) | 50 | $6,875 | $137 |
| Critical care, first 30-74 minutes | 23 | $5,635 | $188 |
| Return visit (30+ min) | 57 | $4,641 | $77 |
| New patient visit (45+ min) | 22 | $2,325 | $106 |
See all 11 services
| Long return visit (40+ min) | 98 | $19,479 | $145 |
| New patient visit (45+ min) | 50 | $6,875 | $137 |
| Critical care, first 30-74 minutes | 23 | $5,635 | $188 |
| Return visit (30+ min) | 57 | $4,641 | $77 |
| New patient visit (45+ min) | 22 | $2,325 | $106 |
| Return visit (30+ min) | 22 | $2,170 | $94 |
| Short return visit (20+ min) | 24 | $1,310 | $50 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 80 | $1,170 | $13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $373 | $27 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 49 | $280 | $5 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 41 | $264 | $6 |
Who their Medicare patients are
287 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 17% · Women 52% · Also on Medicaid 25% · Health risk score 1.60. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 46% · Atrial fibrillation 36% · Diabetes 35% · Heart failure 34% · Chronic kidney disease 32% · Depression 20% · COPD 18% · Cancer 12% · Stroke 11% · Dementia 8%.
The office billed $255,750, Medicare allowed $64,980 and paid $50,419; for 594 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 287 | 594 | 76 | 1.60 | $255,750 | $50,419 |
| 2023 | 384 | 981 | 77 | 1.39 | $284,367 | $57,442 |
| 2022 | 168 | 441 | 68 | 1.46 | $110,647 | $37,075 |
| 2018 | 20 | 48 | 82 | 2.55 | $8,227 | $3,381 |
| 2016 | 75 | 138 | 77 | 1.92 | $13,129 | $6,881 |
| 2015 | 265 | 1,744 | 73 | 1.71 | $258,526 | $191,925 |
| 2014 | 267 | 1,779 | 74 | 1.59 | $391,098 | $185,895 |
| 2013 | 366 | 2,431 | 74 | 1.59 | $689,801 | $283,585 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Return visit (30+ min) | 119 | $13,720 | $99 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 79 | $10,318 | $131 |
| Short return visit (20+ min) | 93 | $8,323 | $76 |
| New patient visit (45+ min) | 47 | $6,215 | $132 |
| New patient visit (30+ min) | 39 | $3,662 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 58 | $3,182 | $55 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $2,269 | $206 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 162 | $1,907 | $11 |
| Long return visit (40+ min) | 11 | $1,555 | $130 |
| Programming of dual lead pacemaker system | 13 | $1,000 | $67 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 15 | $823 | $55 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 39 | $805 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 34 | $577 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 51 | $402 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 34 | $379 | $11 |
| Heart rhythm recording of continous external ekg over 8-15 days | 30 | $296 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 16 | $90 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $72 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $40 | $2 |
2022: 10 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 103 | $12,681 | $120 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $7,141 | $340 |
| Injection, regadenoson, 0.1 mg | 22 | $4,130 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 22 | $3,894 | $88 |
| Ultrasound of leg arteries or artery grafts | 14 | $2,465 | $176 |
| Ultrasound of both sides of head and neck blood flow | 19 | $2,436 | $128 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 25 | $557 | $21 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 22 | $315 | $14 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 21 | $161 | $8 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 37 | $133 | $4 |
2018: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,899 | $59 |
2016: 1 service
| Return visit (30+ min) | 52 | $3,585 | $53 |
2015: 24 services
| Return visit (30+ min) | 184 | $39,337 | $81 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 30 | $29,359 | $947 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 75 | $13,453 | $170 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 34 | $11,908 | $331 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 29 | $10,661 | $355 |
| New patient visit (45+ min) | 64 | $8,219 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,952 | $162 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 15 | $5,690 | $379 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 13 | $4,969 | $355 |
| Short return visit (20+ min) | 65 | $4,614 | $53 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 34 | $4,194 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,208 | $82 |
| New patient visit (60+ min) | 21 | $3,096 | $147 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 32 | $3,082 | $21 |
| Implantation patient-activated heart monitoring device | 18 | $2,426 | $135 |
| Programming of dual lead pacemaker system | 22 | $1,529 | $45 |
| Programming of heart rhythm stimulation after drug infusion | 11 | $1,486 | $135 |
| Long return visit (40+ min) | 13 | $1,481 | $106 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 59 | $961 | $13 |
| Evaluation of cardiac rhythm monitor system | 13 | $436 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 12 | $431 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 15 | $373 | $20 |
| Programming of cardiac rhythm monitor system | 13 | $364 | $28 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 31 | $1 | $0 |
2014: 23 services
| Return visit (30+ min) | 190 | $35,678 | $79 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 27 | $27,357 | $943 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 80 | $14,649 | $168 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 32 | $11,247 | $331 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 27 | $10,306 | $355 |
| New patient visit (60+ min) | 54 | $8,422 | $156 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 21 | $7,809 | $355 |
| Long return visit (40+ min) | 58 | $7,656 | $109 |
| Short return visit (20+ min) | 67 | $5,027 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,948 | $82 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 27 | $3,265 | $117 |
| Implantation patient-activated heart monitoring device | 18 | $2,885 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,629 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,429 | $162 |
| Programming of dual lead pacemaker system | 28 | $1,828 | $46 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 20 | $1,486 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 70 | $1,319 | $13 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 22 | $1,312 | $31 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 22 | $914 | $42 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $526 | $13 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 17 | $510 | $20 |
| Blood test, clotting time | 15 | $279 | $5 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 20 | $1 | $0 |
2013: 29 services
| Return visit (30+ min) | 251 | $55,341 | $77 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 48 | $47,286 | $909 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 56 | $18,837 | $319 |
| New patient visit (60+ min) | 107 | $16,415 | $153 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 105 | $15,055 | $139 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 37 | $13,853 | $338 |
| Long return visit (40+ min) | 83 | $10,884 | $105 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 12 | $9,031 | $695 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 23 | $8,916 | $388 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 23 | $8,628 | $345 |
| Insertion of implantable defibrillator system | 11 | $7,392 | $672 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $7,256 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,543 | $160 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 48 | $5,710 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,803 | $56 |
| New patient visit (45+ min) | 26 | $2,977 | $114 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 123 | $2,479 | $14 |
| Programming of dual lead pacemaker system | 32 | $2,448 | $43 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 15 | $2,427 | None |
| Short return visit (20+ min) | 39 | $2,361 | $51 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 52 | $2,215 | $41 |
| Hospital observation care on day of discharge | 35 | $2,141 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 27 | $1,493 | $55 |
| Ultrasound of heart, follow-up | 16 | $1,236 | $77 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 17 | $1,203 | $33 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $875 | $15 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $824 | $31 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 14 | $494 | $7 |
| Blood test, clotting time | 11 | $111 | $5 |
Medicaid work
$176 in 2024
Medicaid paid $176 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 12 | $176 |
| 2024 | 12 | 1 | 12 | $176 |
| 2023 | 29 | 2 | 15 | $2,037 |
| 2022 | 6,033 | 22 | 102 | $83,257 |
| 2018 | 46 | 1 | 24 | $7,701 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 12 | $1,572 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 17 | $465 |
2022
| Return visit (30+ min) | 1,126 | $35,690 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 326 | $33,875 |
| Short return visit (20+ min) | 247 | $7,610 |
| Tc99m sestamibi | 12 | $2,747 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 12 | $2,542 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 93 | $355 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 104 | $174 |
| External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation | 12 | $122 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 415 | $96 |
| CARDIOVASCULAR STRESS TEST | 65 | $33 |
| External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | 14 | $14 |
| Current tobacco smoker (CAD, CAP, COPD, PV) (DM) | 153 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 46 | $7,701 |
Drugs they prescribed that Part D paid
$109,916
Pharmacies billed $109,916 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 486) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
356 generic and 130 brand-name prescriptions · $109,916 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 58 | $55,372 | $955 |
| Entresto | 18 | $19,401 | $1,078 |
| Jardiance | 12 | $7,081 | $590 |
| Xarelto | 11 | $6,981 | $635 |
| Amiodarone | 30 | $620 | $21 |
See all 15 drugs
| Eliquis | 58 | $55,372 | $955 |
| Entresto | 18 | $19,401 | $1,078 |
| Jardiance | 12 | $7,081 | $590 |
| Xarelto | 11 | $6,981 | $635 |
| Amiodarone | 30 | $620 | $21 |
| Metoprolol | 33 | $586 | $18 |
| Rosuvastatin | 30 | $394 | $13 |
| Losartan | 58 | $347 | $6 |
| Chlorthalidone | 19 | $206 | $11 |
| Amiloride | 19 | $176 | $9 |
| Atorvastatin | 22 | $129 | $6 |
| Amlodipine Besylate | 22 | $129 | $6 |
| Carvedilol | 13 | $78 | $6 |
| Lisinopril | 12 | $55 | $5 |
| Furosemide | 13 | $28 | $2 |
Year by year
| 2024 | 486 | 156 | 0% (0) | 27% | $109,916 |
| 2023 | 786 | 233 | 0% (0) | None | $134,340 |
| 2022 | 578 | 156 | 0% (0) | None | $111,623 |
| 2019 | 48 | 16 | 0% (0) | None | $2,400 |
| 2018 | 154 | 49 | 0% (0) | 29% | $21,984 |
| 2017 | 32 | 21 | 0% (0) | None | $4,391 |
| 2016 | 235 | 56 | 0% (0) | 23% | $31,541 |
| 2015 | 725 | 125 | None | 23% | $70,869 |
| 2014 | 703 | 136 | None | 22% | $63,651 |
| 2013 | 939 | 169 | None | None | $77,027 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Eliquis | 71 | $62,538 | $881 |
| Xarelto | 15 | $11,880 | $792 |
| Losartan | 67 | $1,637 | $24 |
| Metoprolol | 40 | $1,577 | $39 |
| Chlorthalidone | 51 | $1,398 | $27 |
| Rosuvastatin | 37 | $1,341 | $36 |
| Diltiazem 24hr Er (Cd) | 28 | $938 | $33 |
| Amiodarone | 20 | $850 | $42 |
| Atorvastatin | 44 | $763 | $17 |
| Carvedilol | 46 | $741 | $16 |
| Clopidogrel | 15 | $530 | $35 |
| Lisinopril | 46 | $476 | $10 |
| Furosemide | 40 | $414 | $10 |
| Nitroglycerin | 15 | $352 | $23 |
| Spironolactone | 36 | $335 | $9 |
| Amlodipine Besylate | 35 | $221 | $6 |
| Metoprolol | 15 | $118 | $8 |
2022: 18 drugs
| Eliquis | 34 | $36,671 | $1,079 |
| Xarelto | 16 | $17,973 | $1,123 |
| Entresto | 14 | $14,930 | $1,066 |
| Ranolazine Er | 16 | $1,845 | $115 |
| Diltiazem 24hr Er (Cd) | 14 | $915 | $65 |
| Metoprolol | 15 | $622 | $41 |
| Atorvastatin | 42 | $570 | $14 |
| Amiodarone | 14 | $533 | $38 |
| Nitroglycerin | 26 | $450 | $17 |
| Losartan | 20 | $303 | $15 |
| Furosemide | 36 | $282 | $8 |
| Lisinopril | 39 | $277 | $7 |
| Clopidogrel | 13 | $257 | $20 |
| Carvedilol | 28 | $249 | $9 |
| Metoprolol | 23 | $183 | $8 |
| Amlodipine Besylate | 31 | $150 | $5 |
| Spironolactone | 11 | $115 | $10 |
| Hydrochlorothiazide | 16 | $88 | $5 |
2018: 4 drugs
| Eliquis | 24 | $12,987 | $541 |
| Clonidine | 14 | $1,630 | $116 |
| Amiodarone | 12 | $825 | $69 |
| Triamterene-Hydrochlorothiazid | 14 | $111 | $8 |
2016: 4 drugs
| Eliquis | 16 | $12,110 | $757 |
| Sotalol | 48 | $994 | $21 |
| Amiodarone | 19 | $252 | $13 |
| Carvedilol | 14 | $171 | $12 |
2015: 17 drugs
| Eliquis | 55 | $22,658 | $412 |
| Multaq | 17 | $12,907 | $759 |
| Xarelto | 29 | $9,378 | $323 |
| Tikosyn | 11 | $3,692 | $336 |
| Sotalol | 103 | $1,494 | $15 |
| Amiodarone | 44 | $1,089 | $25 |
| Warfarin | 39 | $643 | $16 |
| Midodrine | 13 | $416 | $32 |
| Carvedilol | 44 | $341 | $8 |
| Triamterene-Hydrochlorothiazid | 22 | $278 | $13 |
| Lisinopril | 30 | $174 | $6 |
| Potassium Chloride | 11 | $150 | $14 |
| Spironolactone | 23 | $150 | $7 |
| Amlodipine Besylate | 31 | $130 | $4 |
| Metoprolol | 13 | $124 | $10 |
| Furosemide | 20 | $117 | $6 |
| Hydrochlorothiazide | 17 | $92 | $5 |
2014: 18 drugs
| Xarelto | 51 | $19,061 | $374 |
| Pradaxa | 17 | $7,767 | $457 |
| Eliquis | 14 | $7,082 | $506 |
| Tikosyn | 12 | $3,396 | $283 |
| Sotalol | 83 | $2,146 | $26 |
| Metoprolol | 17 | $1,059 | $62 |
| Clopidogrel | 18 | $917 | $51 |
| Amiodarone | 23 | $898 | $39 |
| Warfarin | 49 | $810 | $17 |
| Carvedilol | 36 | $454 | $13 |
| Lisinopril | 31 | $367 | $12 |
| Simvastatin | 20 | $322 | $16 |
| Amlodipine Besylate | 22 | $306 | $14 |
| Triamterene-Hydrochlorothiazid | 15 | $275 | $18 |
| Atenolol | 14 | $200 | $14 |
| Tamsulosin | 17 | $183 | $11 |
| Furosemide | 24 | $161 | $7 |
| Hydrochlorothiazide | 24 | $127 | $5 |
2013: 24 drugs
| Pradaxa | 32 | $18,334 | $573 |
| Multaq | 11 | $6,162 | $560 |
| Diovan | 11 | $3,680 | $335 |
| Sotalol | 71 | $2,544 | $36 |
| Amiodarone | 28 | $2,275 | $81 |
| Warfarin | 77 | $1,258 | $16 |
| Ramipril | 16 | $755 | $47 |
| Pravastatin | 24 | $704 | $29 |
| Atorvastatin | 14 | $679 | $48 |
| Potassium Chloride | 23 | $659 | $29 |
| Chlorthalidone | 17 | $605 | $36 |
| Simvastatin | 25 | $503 | $20 |
| Carvedilol | 25 | $474 | $19 |
| Lisinopril | 33 | $453 | $14 |
| Amlodipine Besylate | 24 | $415 | $17 |
| Triamterene-Hctz | 17 | $334 | $20 |
| Metoprolol | 31 | $287 | $9 |
| Furosemide | 37 | $279 | $8 |
| Tamsulosin | 12 | $265 | $22 |
| Spironolactone | 23 | $245 | $11 |
| Levothyroxine | 12 | $201 | $17 |
| Jantoven | 18 | $181 | $10 |
| Atenolol | 16 | $178 | $11 |
| Hydrochlorothiazide | 15 | $150 | $10 |
Professional record
- NPI
- 1114927449
- Licence
- CA G45077California G45077: Current · expires 2027-01-31
- Trained
- University of Southern California Keck School of Medicine, 1980
- Group
- Dignity Health Medical Foundation · County of Santa Clara
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- FL 274946700
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X); Federal specialty code 207RC0001X (207RC0001X)
- Mailing address
- 5565 W Las Positas Blvd Ste 150, Pleasanton, CA, 94588
- NPI first listed
- 2005-07-28
- NPI last updated
- 2023-06-05
- NPI record certified
- 2023-06-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2303 Camino Ramon # 208, San Ramon, CA, 94583